p16(INK4a)-induced senescence is disabled by melanoma-associated mutations

by Haferkamp, Sebastian, Becker, Therese M, Scurr, Lyndee L, Kefford, Richard F, Rizos, Helen
Published 2008

A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy

by Kefford, Richard F, Clingan, Philip R, Brady, Benjamin, Ballmer, Andrea, Morganti, Adele, Hersey, Peter
Published 2010

Liquid biomarkers in melanoma: detection and discovery

by Lim, Su Yin, Lee, Jenny H., Diefenbach, Russell J., Kefford, Richard F., Rizos, Helen
Published in Mol Cancer (2018)

Interferon Signaling Is Frequently Downregulated in Melanoma

by Alavi, Sara, Stewart, Ashleigh Jacqueline, Kefford, Richard F., Lim, Su Yin, Shklovskaya, Elena, Rizos, Helen
Published in Front Immunol (2018)

The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence

by Haferkamp, Sebastian, Tran, Sieu L, Becker, Therese M, Scurr, Lyndee L, Kefford, Richard F, Rizos, Helen
Published 2009

Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma

by Menzies, Alexander M., Haydu, Lauren E., Carlino, Matteo S., Azer, Mary W. F., Carr, Peter J. A., Kefford, Richard F., Long, Georgina V.
Published 2014

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series

by Carlino, Matteo S, Vanella, Vito, Girgis, Christina, Giannarelli, Diana, Guminski, Alex, Festino, Lucia, Kefford, Richard F, Menzies, Alexander M, Long, Georgina V, Ascierto, Paolo A
Published in Br J Cancer (2016)

Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling

by Chien, Andy J., Haydu, Lauren E., Biechele, Travis L., Kulikauskas, Rima M., Rizos, Helen, Kefford, Richard F., Scolyer, Richard A., Moon, Randall T., Long, Georgina V.
Published 2014

p16(INK4a) Expression and Absence of Activated B-RAF Are Independent Predictors of Chemosensitivity in Melanoma Tumors

by Gallagher, Stuart J, Thompson, John F, Indsto, James, Scurr, Lyndee L, Lett, Margaret, Gao, Bo-Fu, Dunleavey, Ruth, Mann, Graham J, Kefford, Richard F, Rizos, Helen
Published 2008

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma

by Carlino, Matteo S., Todd, Jason R., Gowrishankar, Kavitha, Mijatov, Branka, Pupo, Gulietta M., Fung, Carina, Snoyman, Stephanie, Hersey, Peter, Long, Georgina V., Kefford, Richard F., Rizos, Helen
Published in Mol Oncol (2014)

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies

by Lee, Jenny H., Long, Georgina V., Menzies, Alexander M., Lo, Serigne, Guminski, Alexander, Whitbourne, Kataraina, Peranec, Michelle, Scolyer, Richard, Kefford, Richard F., Rizos, Helen, Carlino, Matteo S.
Published in JAMA Oncol (2018)

Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma

by Cust, Anne E, Armstrong, Bruce K, Goumas, Chris, Jenkins, Mark A, Schmid, Helen, Hopper, John L, Kefford, Richard F, Giles, Graham G, Aitken, Joanne F, Mann, Graham J
Published 2011

The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16^INK4a

by Mann Graham J, Reisman David N, Scolyer Richard A, Diefenbach Eve, Frausto Monika, Scurr Lyndee L, Dijkstra Menno K, Haferkamp Sebastian, Becker Therese M, Kefford Richard F, Rizos Helen
Published 2009-01-01

The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16(INK4a)

by Becker, Therese M, Haferkamp, Sebastian, Dijkstra, Menno K, Scurr, Lyndee L, Frausto, Monika, Diefenbach, Eve, Scolyer, Richard A, Reisman, David N, Mann, Graham J, Kefford, Richard F, Rizos, Helen
Published 2009

Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors

by Lezcano, Cecilia, Lee, Chung-Wei, Larson, Allison R., Menzies, Alexander M., Kefford, Richard F., Thompson, John F., Mihm, Martin C., Ogino, Shuji, Long, Georgina V., Scolyer, Richard A., Murphy, George F.
Published 2014

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

by Pupo, Gulietta M., Boyd, Suzanah C., Fung, Carina, Carlino, Matteo S., Menzies, Alexander M., Pedersen, Bernadette, Johansson, Peter, Hayward, Nicholas K., Kefford, Richard F., Scolyer, Richard A., Long, Georgina V., Rizos, Helen
Published in Biomark Res (2017)

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

by Lim, Su Yin, Lee, Jenny H., Welsh, Sarah J., Ahn, Seong Beom, Breen, Edmond, Khan, Alamgir, Carlino, Matteo S., Menzies, Alexander M., Kefford, Richard F., Scolyer, Richard A., Long, Georgina V., Rizos, Helen
Published in Biomark Res (2017)

Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA

by Diefenbach, Russell J., Lee, Jenny H., Menzies, Alexander M., Carlino, Matteo S., Long, Georgina V., Saw, Robyn P. M., Howle, Julie R., Spillane, Andrew J., Scolyer, Richard A., Kefford, Richard F., Rizos, Helen
Published in Cancers (Basel) (2020)

Oncogenic B-RAF(V600E) signaling induces the T-box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion

by Boyd, Suzanah C., Mijatov, Branka, Pupo, Gulietta M., Tran, Sieu L., Gowrishankar, Kavitha, Shaw, Heather M., Goding, Colin R., Scolyer, Richard A., Mann, Graham J., Kefford, Richard F., Rizos, Helen, Becker, Therese M.
Published 2012

MC1R genotypes and risk of melanoma before age 40 years: a population-based case-control-family study

by Cust, Anne E, Goumas, Chris, Holland, Elizabeth A, Agha-Hamilton, Chantelle, Aitken, Joanne F, Armstrong, Bruce K, Giles, Graham G, Kefford, Richard F, Schmid, Helen, Hopper, John L, Mann, Graham J, Jenkins, Mark A
Published in Int J Cancer (2012)